Updated guidance on identification and strategies for management
Q&A with the director of our dedicated program for statin intolerance
Also finds PCSK9 inhibitor more potent than ezetimibe in statin-intolerant patients
Further lowering LDL reduces risk in post-ACS patients
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy